AMGN Today - Aug 08: EMA Backs Repatha Use
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
AMGN Today - Aug 08: EMA Backs Repatha Use
-
Letto da:
-
Di:
A proposito di questo titolo
So, what went down? Amgen popped up after some good news from the European Medicines Agency. They gave a thumbs up for broader use of Amgen's heart drug Repatha in high-risk patients. That’s always a boost for a company when regulators back their products. People were feeling it, and the stock got some nice momentum.
Now, here’s where it gets interesting. While the good news was rolling in, there were also some mixed signals. One of Amgen's top execs, Nancy Grygiel, sold off over a million bucks worth of stock. That’s a big move, and it kinda makes people raise an eyebrow. Is she cashing in before something changes? Who knows, but it definitely had some folks hitting the sell button. Also, we saw some changes in holdings with other firms. Teamwork Financial Advisors sold off a chunk, while MRA Advisory Group decided to grab more shares. It’s like a tug-of-war with the stock!
Looking ahead, Amgen’s got some more eyes on it since the Repatha news. Investors will be watching closely to see how that plays out in the next earnings report.
To wrap this up, Amgen had a decent day thanks to solid news about Repatha, but there’s also some caution in the air with those insider sales. Just remember, this is all for your info and fun—no buy or sell tips from me. Catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione